Back to News
Market Impact: 0.45
Merck and Moderna's Cancer Vaccine Worked—Who Gets Paid?
Source: marketbeat.com
Healthcare & Biotech
Merck & Co. and Moderna said their personalized melanoma vaccine succeeded in a Phase 3 trial, a milestone the article says no cancer vaccine had previously achieved. The article provides no efficacy figures, approval status, or further trial details.
AllMind Terminal
AI-powered research, real-time alerts, and portfolio analytics for institutional investors.
Request TrialMarket Sentiment
Overall Sentiment
moderately positive
Sentiment Score
0.55
Ticker Sentiment
MRK0.80
MRNA0.80
More News
- Moderna shares slip as William Blair cuts rating on valuation after rally
- Artiva halts AlloNK development, cuts 94% of workforce
- Universal Health Services falls 3% on legal settlement concerns
- Midterm elections: How affordability and the economy could impact voters
- Why is Artiva Biotherapeutics stock collapsing today?
- adar1 capital management buys $53,691 of NextCure stock